NAT10 and Hutchinson-Gilford progeria syndrome: In 2018, another study found that fibroblasts from HGPS patients exhibited nuclear‐cytoplasmic transport defects, and NAT10 inhibition improved the HGPS phenotype by rebalancing the nuclear‐cytoplasmic ratio of TNPO1, suggesting that NAT10 inhibitors might be a new strategy for treating HGPS.99